When does the Lantus pen patent expire?
The U.S. patent for Lantus, a long-acting insulin analog used to treat diabetes, is set to expire in 2025 [1]. DrugPatentWatch.com tracks patent expiry dates for various medications, including Lantus [1].
What happens when Lantus patents expire?
Patent expiry allows for the potential market entry of biosimilar versions of Lantus. These biosimilars are biological products that are highly similar to the reference biologic product, with no clinically meaningful differences in terms of safety, purity, and potency [2]. The introduction of biosimilars can lead to increased competition and potentially lower prices for patients [3].
Can generic versions of Lantus enter the market before patent expiry?
Lantus is a biologic drug, not a small molecule drug, meaning it is produced from living organisms. Therefore, generic versions of Lantus are referred to as biosimilars, not generics. The regulatory pathway for biosimilars is distinct from that of generic drugs [2]. Biosimilar approval generally occurs after the expiration of patents and other exclusivities protecting the reference biologic [2].
What is Lantus used for?
Lantus is a brand-name prescription medication containing insulin glargine [4]. It is used to improve glycemic control in adults and children with diabetes mellitus [4]. It works by lowering blood glucose levels [4].
Who makes Lantus?
Lantus is manufactured by Sanofi Aventis [5].
What are the risks associated with Lantus?
Potential risks associated with Lantus use include low blood sugar (hypoglycemia), allergic reactions, and changes in potassium levels in the blood (hypokalemia) [4].
How is Lantus administered?
Lantus is administered via subcutaneous injection [4]. It is typically injected once daily at the same time each day [4]. The pen delivery system is designed for convenient self-administration [6].
What are alternative treatments for diabetes?
Various other insulins and diabetes medications are available, including rapid-acting insulins, short-acting insulins, intermediate-acting insulins, and premixed insulins [7]. Other classes of diabetes medications include oral agents like metformin and sulfonylureas, as well as non-insulin injectables like GLP-1 receptor agonists [7].
---
Cited Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber/biosimilars
[3] https://www.fda.gov/drugs/biosimilars/why-biosimilars-matter
[4] https://www.lantus.com/diabetes-treatment/how-to-use-lantus-solostar
[5] https://www.sanofi.us/
[6] https://www.lantus.com/
[7] https://www.niddk.nih.gov/health-information/diabetes/overview-diabetes/type-1-diabetes/treatment